Страна: Европейски съюз
Език: английски
Източник: EMA (European Medicines Agency)
tetanus toxoid
Intervet International BV
QI05AB03
Adjuvanted vaccine against tetanus
Horses
Immunologicals for equidae
Active immunisation of horses from 6 months of age against tetanus to prevent mortality.Onset of immunity: 2 weeks after the primary vaccination courseDuration of immunity: 17 months after the primary vaccination course, 24 months after the first revaccination
Revision: 8
Authorised
2005-07-08
13 B. PACKAGE LEAFLET 14 PACKAGE LEAFLET FOR EQUILIS TE SUSPENSION FOR INJECTION FOR HORSES 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Te suspension for injection for horses 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each dose of 1 ml contains: ACTIVE SUBSTANCE: Tetanus toxoid 40 Lf 1 1 Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig serum in the Ph. Eur. potency test ADJUVANTS: Purified Saponin 375 µg Cholesterol 125 µg Phosphatidylcholine 62.5 µg A clear opalescent suspension. 4. INDICATION(S) Active immunisation of horses from 6 months of age against tetanus to prevent mortality. Onset of immunity: 2 weeks after the primary vaccination course Duration of immunity: 17 months after the primary vaccination course 24 months after the first revaccination 5. CONTRAINDICATIONS None. 6. ADVERSE REACTIONS A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur at the injection site, regressing within 2 days. In very rare cases a local reaction exceeding 5 cm and possibly persisting longer than 2 days may occur. Pain at the injection site can occur in rare cases which may result in temporary functional discomfort (stiffness). In very rare cases, fever, sometimes accompanied by lethargy and inappetence, may occur for 1 day, and up to 3 days in exceptional circumstances. 15 The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). If y Прочетете целия документ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Te suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains: ACTIVE SUBSTANCE: Tetanus toxoid 40 Lf 1 1 Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig serum in the Ph. Eur. potency test ADJUVANTS: Purified Saponin 375 µg Cholesterol 125 µg Phosphatidylcholine 62.5 µg For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Suspension for injection. Clear opalescent suspension. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of horses from 6 months of age against tetanus to prevent mortality. Onset of immunity: 2 weeks after the primary vaccination course Duration of immunity: 17 months after the primary vaccination course 24 months after the first revaccination 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Foals should not be vaccinated before the age of 6 months, especially when born to mares that were revaccinated in the last two months of gestation, because of possible interference by maternally derived antibodies. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Only healthy animals should be vaccinated. 3 Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur at the injection site, regressing within 2 days. In very rare cases a local reaction exceeding 5 cm and possibly persisting longer than 2 days may occur. Pain at the injection site can occur in rare cases which may result in temporary functional discomfort (stiffness). In very rare cases, fever, sometimes accompanied by lethargy and inappetence, may occ Прочетете целия документ